In The News

The LEADER Study: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

This randomized, double-blind trial evaluated the cardiovascular (CV) effects of liraglutide versus placebo in patients with type 2 diabetes and high cardiovascular rish. The composite primary outcome of this time-to-event noninferiority trial included the first occurrence of death from CV causes, nonfatal myocardial infarction, or nonfatal stroke. A total of 9,340 patients were followed for a median of 3.8 years.

Once-Daily Delayed-Release Metformin Lowers Plasma Glucose and Has Similar Effect on Gut Hormones Compared With Immediate-Release Metformin

Two small, randomized controlled, crossover trials (one blinded, one not) were conducted to evaluate the gut-based action of a delayed-release (DR) formulation of metformin vs immediate-release (IR) metformin. Patients receiving metformin DR had an almost 60% reduction in systemic drug exposure compared with metformin IR. However, both treatments similarly decreased fasting and postprandial glucose, led to similar gut hormone responses, and had similar adverse event profiles.

FDA Approves Extended-Release Linagliptin/Metformin Combination

May 31, 2016. The US Food and Drug Administration has approved a once-daily, extended-release oral combination of the dipeptidyl peptidase-4 inhibitor linagliptin and metformin to treat adults with type 2 diabetes. The tablets combine 2.5 mg or 5.0 mg linagliptin with 1000 mg metformin. You can read the full article here.

Insulin Degludec/Liraglutide Combination Therapy Recommended by FDA Panel

May 24, 2016. A US Food and Drug Administration advisory committee unanimously recommended the approval of IDegLira, a combination of insulin degludec and liraglutide, for the treatment of type 2 diabetes. Although the formulation’s safety is not under question, concerns were raised regarding the clinical utility of IDegLira. Specifically, the methodology of clinical trials and insulin/liraglutide dosing methods were called into question. Advisers also noted that a clear target group for this formulation has not yet been identified.

Canagliflozin/Metformin Combo Approved as First Line for Diabetes

May 24, 2016. The US Food and Drug Administration has approved Invokamet, a fixed-dose combination of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and metformin, for the first-line treatment of adults with type 2 diabetes.You can read the full article here.

FDA Drug Safety Communication: Interim Results Find Increased Risk of Leg/Foot Amputations With Canagliflozin

March 18, 2016. The US Food and Drug Administration (FDA) has issued a public alert regarding interim safety results for the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin, obtained from an ongoing clinical trial of the drug. Specifically, an increased prevalence in leg and foot amputations has been observed, mostly affecting the toes, in patients treated with canagliflozin. The FDA is investigating this issue and will update the public when they have more information. You can read the full article here.

Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes

April 19, 2016. This systematic review and meta-analysis was conducted to evaluate the comparative effectiveness of various monotherapies and selected metformin-based combinations available to treat type 2 diabetes (T2D). The study evaluated thiazolidinediones, metformin, sulfonylureas, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists, along with selected metformin-based combinations. A total of 179 head-to-head studies and 25 observational studies were evaluated.

Hypoglycemia Risk With Addition of Dipeptidyl Peptidase-4 Inhibitors to Sulfonylureas

May 3, 2016. This systematic review and meta-analysis quantified hypoglycemia risk associated with the use of dipeptidyl-peptidase-4 (DPP-4) inhibitors and sulfonylureas versus placebo and sulfonlyureas. Ten studies, representing 6546 patients, were selected for analysis. The sulfonylureas evaluated were glimepiride and glyburide, with some studies not specifying drug names. The risk ratio for hypoglycemia with DPP-4 inhibitors was 1.52 (95% confidence interval 1.29 to 1.80) compared with placebo.

FDA Issues Drug Safety Communication Related to Ongoing Safety Review of Insulin Glargine and Possible Cancer Risk

May 4, 2016. The US Food and Drug Administration (FDA) has released an update regarding its ongoing investigation of insulin glargine (Lantus) use and possible cancer risk. In this announcement, the FDA outlines the key literature it has reviewed since this investigation was started in 2009. At this time, the FDA has not concluded that Lantus increases cancer risk. This review is ongoing, and the FDA will update the public when it has additional information. Follow this link to read the FDA Safety Announcement.

American Association of Clinical Endocrinologists and American College of Endocrinology Issue Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis

May 2016. Recent reports of diabetic ketoacidosis (DKA) occurring in conjunction with sodium glucose-cotransporter 2 (SGLT-2) inhibitor therapy have raised concerns that these agents may increase the risk of DKA, especially among insulin-using patients. To address these concerns, the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) convened a public conference in which experts from Europe and the United States evaluated relevant cases and clinical data.